Oct 01, 2018
|
Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines
|
|
Sep 11, 2018
|
Vertex to Present at the Morgan Stanley Healthcare Conference on September 14
|
|
Sep 10, 2018
|
Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility
|
|
Sep 06, 2018
|
Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis
|
|
Sep 03, 2018
|
Vertex Announces Reimbursement Agreement in Australia for ORKAMBI® (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation
|
|
Aug 30, 2018
|
Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines
|
|
Aug 23, 2018
|
Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations
|
|
Aug 20, 2018
|
Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation
|
|
Aug 16, 2018
|
Vertex Awards Two College Students Full Scholarships to the University of Massachusetts
|
|
Aug 15, 2018
|
FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene
|
|
Aug 07, 2018
|
FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease
|
|
Jul 27, 2018
|
Vertex Receives European CHMP Positive Opinion for SYMKEVI® (tezacaftor/ivacaftor) for People with Cystic Fibrosis Aged 12 and Older with Certain Mutations in the CFTR Gene
|
|
Jul 25, 2018
|
Vertex Reports Second-Quarter 2018 Financial Results
|
|
Jul 12, 2018
|
Vertex to Announce Second Quarter 2018 Financial Results on July 25
|
|
Jun 28, 2018
|
Health Canada Approves PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene
|
|
Jun 21, 2018
|
Vertex’s Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis
|
|
Jun 18, 2018
|
Vertex Opens Expanded Research Site in San Diego
|
|
Jun 18, 2018
|
Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)
|
|
Jun 14, 2018
|
The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program
|
|
Jun 07, 2018
|
Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF
|
|